Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 6c
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Join SI Premium – FREE
Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.22), $0.06 better than the analyst estimate of ($0.28).
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
- Acacia Research (ACTG) Tops Q2 EPS by 22c
- Icahn Enterprises L.P. (IEP) Misses Q2 EPS by 64c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
